Perspective Therapeutics (NYSE:CATX) Raised to Moderate Buy at Royal Bank of Canada
Perspective Therapeutics (NYSE:CATX – Get Free Report) was upgraded by research analysts at Royal Bank of Canada from an “outperform” rating to a “moderate buy” rating in a note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a $16.00 target price on the stock, up from their prior target price of […]
Perspective Therapeutics (NYSE:CATX – Get Free Report) was upgraded by research analysts at Royal Bank of Canada from an “outperform” rating to a “moderate buy” rating in a note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a $16.00 target price on the stock, up from their prior target price of […]
